Programmed Cell Death in Cancer

Area of Science:

• Oncology
• Cell Biology
• Molecular Medicine

Background:

• Cancer remains a leading global cause of death despite advances in treatment.
• Dysregulation of programmed cell death (PCD) pathways contributes to cancer initiation and resistance to therapies.
• Understanding PCD mechanisms is vital for developing effective cancer treatments.

Purpose of the Study:

• To provide a comprehensive review of the discovery, roles, and mechanisms of major PCD forms in cancer.
• To explore the interconnections and crosstalk between different PCD modalities.
• To discuss the manipulation of PCD pathways by various cancer therapies and highlight therapeutic opportunities, with a focus on ferroptosis and prostate cancer.

Main Methods:

• Comprehensive literature review of preclinical and clinical evidence.
• Synthesis of molecular mechanisms, dual functions, and alterations of PCD pathways in various cancer types.
• Analysis of therapeutic strategies targeting PCD, including chemotherapy, radiotherapy, immunotherapy, and targeted agents.

Main Results:

• Detailed overview of apoptosis, necroptosis, autophagy, pyroptosis, ferroptosis, and cuproptosis in cancer.
• Elucidation of the complex crosstalk and interconnections among different PCD pathways.
• Demonstration of how diverse cancer therapies engage and modulate specific PCD pathways.

Conclusions:

• Programmed cell death pathways are intricately linked to cancer biology and therapeutic responses.
• Targeting specific PCD modalities, particularly ferroptosis, offers promising translational opportunities for precision oncology.
• Further research into PCD mechanisms and their manipulation can lead to novel and more effective cancer treatment strategies, especially in malignancies like prostate cancer.